ARK Weekly Roundup: Tesla Robotaxi Roadmap, AlphaGenome, Genetic Medicine, SpaceX-xAI, Grail MCED

[!warning] Conflict of Interest ARK Invest is an active fund manager promoting its own positions. ARK holds TSLA, genomics stocks, and other names mentioned here. Read with appropriate skepticism — they are talking their book.

Key Themes

• Tesla robotaxi expansion: Fleet logged ~650K miles through Dec 2025 with ~500 vehicles in Austin and Bay Area. ARK projects Tesla could surpass Waymo’s ~3,000 vehicle fleet within three months. ARK claims Cybercab hardware could be ~50% less expensive per mile than Waymo’s sixth-gen robotaxi, enabling ~$0.25/mile pricing at scale. They frame a ~$34 trillion enterprise value opportunity by 2030.
• DeepMind AlphaGenome: New AI model analyzing up to 1M DNA base pairs to predict how non-coding DNA (98% of genome) regulates gene activity. Extends AlphaFold work. Could help prioritize causal disease variants and inform targeted genetic medicines.
• Genetic medicine flurry: Intellia’s nex-z CRISPR therapy clinical hold lifted for ATTR-PN trial. REGENXBIO gene therapies placed on hold after brain neoplasm in pediatric patient. Life Biosciences received FDA clearance for first-in-human epigenetic “reset” trial targeting optic nerve damage. Eli Lilly partnered with Seamless Therapeutics on programmable recombinase therapies.
• SpaceX-xAI merger speculation: Polymarket odds ~62% for SpaceX-xAI merger vs ~13% for SpaceX-Tesla. A combined entity would give xAI access to SpaceX orbital data centers.
• Grail MCED test: FDA PMA submission for Galleri multi-cancer early detection test. Pathfinder 2 study showed 99.6% specificity, 40% overall sensitivity (73% for most lethal cancers). NHS-Galleri trial readout expected mid-2026 to prove mortality benefits. Medicare coverage legislation advancing.

RDCO Relevance

Genomics and AI convergence themes are relevant to broader automated investing research. Tesla robotaxi valuation models worth monitoring against reality. MCED/Grail progression relevant as healthcare innovation signal.